Twenty-one-year follow-up of variable onset MELAS syndrome with heteroplasmic nt3243A>G mtDNA mutation: A case report
Journal of Genetic Medicine
; : 31-38, 2019.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-764506
Responsible library:
WPRO
ABSTRACT
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a maternally inherited mitochondrial disorder of which m.3243A>G is the most commonly associated mutation, resulting in an inability to meet the energy requirements of various organs. MELAS poses a diagnostic challenge owing to its multiple organ involvement and great clinical variability due to its heteroplasmic nature. We report three cases from a family who were initially misdiagnosed with myasthenia gravis or undiagnosed. Although there is no optimal consensus treatment approach for patients with MELAS because of the disease's heterogeneity, our 21-year-long therapy regimen of l-arginine, l-carnitine, and coenzyme Q10 supplementation combined with dietary management appeared to provide noticeable protection from the symptoms and complications. Prompt early diagnosis is important, as optimal multidisciplinary management and early intervention may improve outcomes.
Full text:
Available
Health context:
SDG3 - Health and Well-Being
Health problem:
Target 3.4: Reduce premature mortality due to noncommunicable diseases
Database:
WPRIM (Western Pacific)
Main subject:
Arginine
/
Population Characteristics
/
Acidosis, Lactic
/
DNA, Mitochondrial
/
Carnitine
/
Follow-Up Studies
/
MELAS Syndrome
/
Early Intervention, Educational
/
Mitochondrial Diseases
/
Consensus
Type of study:
Diagnostic study
/
Practice guideline
/
Observational study
/
Prognostic study
/
Screening study
Aspects:
Social determinants of health
Limits:
Humans
Language:
English
Journal:
Journal of Genetic Medicine
Year:
2019
Document type:
Article